The Current Ratio as of December 2024 (TTM) for Pharvaris N.V. (PHVS) is 19.08

According to Pharvaris N.V.’s latest financial reports and current stock price. The company's current Current Ratio is 19.08. This represents a change of -10.54% compared to the average of 21.32 of the last 4 quarters.

Pharvaris N.V. (PHVS) Historical Current Ratio (quarterly & annually)

How has PHVS Current Ratio performed in the past?

The mean historical Current Ratio of Pharvaris N.V. over the last ten years is 20.32. The current 19.08 Current Ratio has changed 9.29% with respect to the historical average. Over the past ten years (40 quarters), PHVS's Current Ratio was at its highest in in the March 2017 quarter at 34.55. The Current Ratio was at its lowest in in the March 2023 quarter at 7.96.

Pharvaris N.V. (PHVS) Current Ratio by Quarter and Year

Discovering the peaks and valleys of Pharvaris N.V. Current Ratio, unveiling quarterly and yearly fluctuations to gain insights into the company’s financial performance and market dynamics, offering valuable data for investors and analysts alike.

Pharvaris N.V. (PHVS) Average Current Ratio

How has PHVS Current Ratio performed in the past?

The current Current Ratio of Pharvaris N.V. (PHVS) is less than than its 3-year, less than than its 5-year, and less than than its 10-year historical averages

Pharvaris N.V. (PHVS) Current Ratio vs. Peers

How is PHVS’s Current Ratio compared to its peers?

Pharvaris N.V.’s Current Ratio is greater than PMV Pharmaceuticals, Inc. (13.98), less than Eliem Therapeutics, Inc. (0), greater than MediciNova, Inc. (16.66), greater than PepGen Inc. (8.47), greater than Molecular Partners AG (14.33), greater than Mineralys Therapeutics, Inc. (8.55), greater than AN2 Therapeutics, Inc. (9.75), greater than Monte Rosa Therapeutics, Inc. (6.03), less than Design Therapeutics, Inc. (34.61), greater than Werewolf Therapeutics, Inc. (10.10), greater than Ikena Oncology, Inc. (15.32), greater than Stoke Therapeutics, Inc. (5.09), less than Tyra Biosciences, Inc. (29.55), greater than Anebulo Pharmaceuticals, Inc. (3.45), less than Janux Therapeutics, Inc. (38.80), greater than Rezolute, Inc. (13.79),

Build a custom stock screener for Pharvaris N.V. (PHVS) and other stocks

One of the best ways to find valuable stocks to invest in is to build a custom made screener in your Excel or Google Sheets spreadsheet. This allows you to compare thousands of companies like Pharvaris N.V. using the financials and key metrics that matter to you in a single view.

The easiest way to set this up is to use the Wisesheets add-on and set your spreadsheet like this:

Covering all these metrics from financial, data, dividend data, key metrics and more you can get all the data you want for over 50+ exchanges worldwide.

Get your free trial here.

Pharvaris N.V. (PHVS) and other stocks custom spreadsheet templates

The easiest way to analyze a company like Pharvaris N.V. or any others is to create a spreadsheet model that automatically retrieves all of the stock data you need.

Using Wisesheets you can set up a spreadsheet model like this with simple spreadsheet formulas. If you change the ticker you can get all of the data automatically updated for you.

Whether you need live data, historical price data, financials, dividend data, key metrics, analyst estimates, or anything else...Wisesheets has you covered.